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The pathophysiologic continuum of non-alcoholic
fatty liver disease begins with steatosis. Despite
recent advances in our understanding of the gene
regulatory program directing steatosis, how it is
orchestrated at the chromatin level is unclear.
PPARg2 is a hepatic steatotic transcription factor
induced by overnutrition. Here, we report that the
histone H3 lysine 4 methyltransferase MLL4/KMT2D
directs overnutrition-induced murine steatosis via
its coactivator function for PPARg2.We demonstrate
that overnutrition facilitates the recruitment of MLL4
to steatotic target genes of PPARg2 and their
transactivation via H3 lysine 4 methylation because
PPARg2 phosphorylated by overnutrition-activated
ABL1 kinase shows enhanced interaction with
MLL4. We further show that Pparg2 (encoding
PPARg2) is also a hepatic target gene of ABL1-
PPARg2-MLL4. Consistently, inhibition of ABL1 im-
proves the fatty liver condition ofmicewith overnutri-
tion by suppressing the pro-steatotic action of MLL4.
Our results uncover a murine hepatic steatosis
regulatory axis consisting of ABL1-PPARg2-MLL4,
which may serve as a target of anti-steatosis drug
development.INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) shows a spectrum
of liver pathology that resembles alcohol-induced fatty liver
damage (Hardy et al., 2016). Because of its strong association
with the widespread metabolic syndrome, NAFLD is also
becoming epidemic and the leading cause of chronic liver
disease in developed countries. Furthermore, a subset of indi-Cell Rep
This is an open access article undviduals with NAFLD develop non-alcoholic steatohepatitis
(NASH), and some of these NASH patients eventually develop
cirrhosis and/or liver cancer (Hardy et al., 2016). In line with
the notion that NAFLD is a major health risk, numerous
studies have been performed to obtain a better understanding
of the epidemiology, etiology, pathophysiology, and therapeutic
intervention of the disease. In particular, triglyceride (TG) is an
ester of three free fatty acids (FFAs) bound to glycerol, and
the pathophysiologic continuum of NAFLD begins with accu-
mulation of TGs within hepatocytes (i.e., hepatic steatosis).
Despite great advances in our understanding of the gene regu-
latory program directing hepatic steatosis (Hardy et al., 2016),
it is poorly understood how this program is orchestrated
epigenetically.
We previously purified the two founding members of a family
of the six mammalian SET1-like complexes (Lee et al., 2009)
containing either the histone H3 lysine 4 methyltransferase
(H3K4MT) mixed-lineage leukemia 3 (MLL3/KMT2C) or its
closest paralog, MLL4/KMT2D (Goo et al., 2003; Lee et al.,
2006). Each mammalian SET1-like complex contains one of
the six H3K4MTs, SET1A/B and MLL1-4, complex-specific
subunits, and a common subcomplex consisting of Rbbp5,
Ash2l, Wdr5, and Dpy30, which facilitates the H3K4MT activity
of SET1A/B/MLL1-4 (Lee et al., 2009). The MLL3/4 complexes
were subsequently identified to also contain the histone H3
lysine 27 (H3K27) demethylase UTX (Agger et al., 2007; Hong
et al., 2007; Lan et al., 2007; Lee et al., 2007; Smith et al.,
2008). Their unique subunits, such as ASC-2/NCOA6 and
PTIP, have been shown to serve as adaptors that recruit
the non-DNA-binding epigenetic transcriptional coactivators
MLL3/4 and UTX to enhancers of their target genes by
directly interacting with specific transcription factors bound to
those enhancers (Lee et al., 2009). In particular, ASC-2, using
its two LXXLL motifs that recognize the activated conforma-
tion of nuclear receptors (NRs), has been suggested to tether
MLL3/4/UTX to their target enhancers occupied by several
NRs (Choi et al., 2005; Kim et al., 2003, 2009a, 2009b, 2015;
Lee et al., 2006, 2008a, 2008b; Surapureddi et al., 2008),orts 17, 1671–1682, November 1, 2016 ª 2016 The Authors. 1671
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triggering their target genes to form open chromatin for trans-
activation. Although UTX removes the repressive chromatin
mark histone H3 lysine 27-trimethylation (H3K27me3) (Agger
et al., 2007; Hong et al., 2007; Lan et al., 2007; Lee et al.,
2007; Smith et al., 2008), MLL3/4 have been suggested to
function through directing the mono- and di-methylation of
H3K4 residues (histone H3 lysine 4-monomethylation/histone
H3 lysine 4-dimethylation [H3K4me1/2]) of their target en-
hancers (Ang et al., 2016; Guo et al., 2013; Hu et al.,
2013; Lee et al., 2013). Interestingly, epigenetic regulation of
diverse metabolic processes has been defined as one of
the key physiological functions of MLL3/4 complexes (Kim
et al., 2003, 2009a, 2009b; Lee et al., 2008a, 2008b; Surapur-
eddi et al., 2008). However, the exact identity of their
target genes/enhancers responsible for each of these meta-
bolic processes as well as the transcription factors that
recruit MLL3/4 complexes to those genes remain to be further
defined.
TheNR, peroxisome proliferator activated receptor g (PPARg),
is a master adipogenic transcription factor (Medina-Gomez
et al., 2007; Vidal-Puig et al., 1996). The expression of PPARg2,
a more adipogenic isoform of PPARg, is normally restricted to
white and brown adipose tissue but ectopically induced in liver
and skeletal muscle in response to overnutrition or genetic
obesity (Medina-Gomez et al., 2007; Tontonoz et al., 1994; Vi-
dal-Puig et al., 1996). Consistent with the notion that overnutri-
tion causes endoplasmic reticulum (ER) stress (Hummasti and
Hotamisligil, 2010), which results from a disequilibrium between
the folding capacity of the ER and the amount of proteins to
be folded, ER stress is observed in the lipid excess livers of
ob/ob and high-fat diet (HFD)-fed mice (Ozcan et al., 2004).
ER stress is also known to activate ABL1 kinase (Ito et al.,
2001; Pattacini et al., 2004; Qi and Mochly-Rosen, 2008).
Raising the interesting idea that ABL1 kinase is a key effector
of fat storage in response to overnutrition, ABL1 kinase has
recently been demonstrated to be a positive regulator of
adipogenesis (Keshet et al., 2014). During adipogenesis,
ABL1 binds to the PPARg2 isoform-specific N-terminal region
of PPARg2 and phosphorylates two tyrosine residues in the
AF1 domain of PPARg2, which increases the protein stability
of PPARg2 as well as the binding affinity of PPARg2 to its tran-
scriptional coactivator, PPAR g coactivator 1a (PGC1a), lead-
ing to an enhancement in PPARg2 transactivation potential
(Keshet et al., 2014).
In this report, using a combination of HFD-induced hepatic
steatosis paradigm and unbiased genome-wide RNA se-
quencing (RNA-seq) analyses, we establish MLL4 as a critical
regulator of overnutrition-induced hepatic steatosis. We also
demonstrate that this function of MLL4 is mainly mediated by
PPARg2 because MLL4 preferentially binds to PPARg2 over
PPARg1, likely via PPARg2-specific phosphorylation by HFD-
activated ABL1 kinase in the liver. We further show that imatinib,
an ABL1 inhibitor, suppresses the pro-steatotic action of MLL4
and improves the fatty liver condition of ob/ob and HFD-fed
mice. Overall, our results uncover a critical regulatory axis in
overnutrition-directed hepatic steatosis and present this ABL1-
PPARg2-MLL3/4 axis as a potential target for anti-steatosis
drug development.1672 Cell Reports 17, 1671–1682, November 1, 2016RESULTS
Resistance of Mll3/4 Mutant Mice to HFD-Induced
Hepatic Steatosis
We have reported previously that homozygous mutant mice ex-
pressing a catalytically inactive deletion form of MLL3, named
Mll3D/D, are resistant to fatty liver formation induced by HFD
(Lee et al., 2008a, 2008b). Because our previous studies indi-
cated that MLL3 and MLL4 play similar roles in several meta-
bolic processes (Kim et al., 2009a, 2015; Lee et al., 2008a,
2008b), we hypothesized that Mll4 mutant mice may also
show resistance to HFD-induced hepatic steatosis. Although
our Mll4/ mice displayed early embryonic lethality, Mll4+/
mice survived into adulthood (Kim et al., 2015). To test our hy-
pothesis, we subjected Mll4+/ mice to 16 weeks of HFD
feeding. Indeed, like Mll3D/D mice, Mll4+/ mice were resistant
to HFD-induced hepatic steatosis (Figure 1A). Oil red O staining
confirmed that Mll4+/ livers accumulated much less fat relative
to wild-type (WT) littermate control livers after 16 weeks of HFD
feeding (Figure 1B). These mouse genetic results suggest that
MLL3 and MLL4 likely function similarly in directing fatty liver
formation.
Critical Roles of MLL4 in HFD-Dependent
Transcriptome Changes of the Mouse Liver
The dramatic difference between control and Mll3/4 mutants in
HFD-induced fatty liver formation (Figures 1A and 1B; Lee
et al., 2008a, 2008b), together with the notion that MLL3/4 act
as transcriptional coactivators, raises the interesting possibility
that MLL3/4 may play critical roles in HFD-dependent transcrip-
tome changes in the mouse liver. To test this idea, we performed
RNA-seq using the livers of 8-week-old WT and Mll4+/ male
mice fed either a normal chow diet (CD) or HFD for 8 weeks.
These analyses identified 272 genes whose expression showed
more than a 1.5-fold difference between CD- and HFD-fed WT
livers (false discovery rate < 10%), consisting of 153 HFD-
induced genes and 119 HFD-suppressed genes (Figure 1C).
Among the 153 HFD-induced genes in WT livers, we identified
100 genes (65%) whose expression was less efficiently upre-
gulated by HFD in Mll4+/ livers (more than 1.5-fold change be-
tween Mll4+/ and WT under HFD conditions; false discovery
rate < 10%; Figures 1C and 1D; Table S1). Among the 119
HFD-suppressed genes in WT livers, we identified 61 genes
(51%) whose expression was already downregulated in
Mll4+/ livers under CD conditions (more than 1.5-fold change
between Mll4+/ and WT; false discovery rate < 10%; Figures
1C and 1D; Table S2). These results demonstrate that the
expression of a large portion of HFD-controlled genes (161 of
272 genes, 60%) require MLL4, establishing a critical role for
MLL4 in HFD-dependent transcriptome changes in the mouse
liver.
Identification of Steatotic Genes as Major Targets of
MLL3/4 in the Liver
Given the resistance of Mll3/4 mutants to HFD-induced fatty
liver formation, we hypothesized that the HFD-dependent tran-
scriptome changes of the mouse liver directed by MLL4 (Fig-
ures 1C and 1D) likely involve hepatic steatotic genes. We
Figure 1. Resistance of Mll4+/ Mice to
HFD-Induced Steatosis
(A) Gross morphology of livers from WT and
Mll4+/ mice fed an HFD for 16 weeks.
(B) Oil red O staining to visualize lipids in the livers
in (A). Scale bar, 100 mm.
(C) Schematic of the notion that a significant
portion of HFD-regulated genes require MLL4 in
their response to an HFD.
(D) Heatmap for genes that require MLL4 for their
up- or downregulation by an HFD.
See also Tables S1 and S2.recently determined the transcriptome changes in the livers of
5-month-old WT, Mll3+/D, Mll4+/, and Mll3+/D;Mll4+/ mice us-
ing RNA-seq, identifying genes that are either positively or
negatively regulated by MLL3/4 in the liver (Kim et al., 2015).
In support of our hypothesis, gene ontology (GO) analyses of
the positively regulated target genes of MLL3/4 revealed the
GO term ‘‘lipid synthesis’’ (Kim et al., 2015). Surprisingly, further
analysis of the genes in this GO category disclosed that they
belong to three specific input pathways for hepatic FFAs and
TGs; i.e., FFA uptake, de novo fatty acid synthesis, and lipid
droplet synthesis (Figure 2A). Moreover, an identical GO term
(i.e., lipid synthesis) and a similar set of genes were also iden-
tified from further analysis of the 100 HFD-inducible genes that
required MLL4 (Figure 2B; Figure S1A). Notably, the 161 HFD-
induced/repressed genes produced only four prominent GOCell Reporterms, and the GO term for lipid synthe-
sis was statistically most significant (Fig-
ure S1A). Some of these RNA-seq
results were independently validated
(Figures S1B—S1D). Our results suggest
that specific activation of the expression
of genes involved in input pathways for
hepatic FFAs and TGs is a major mech-
anism MLL3/4 employ to direct hepatic
steatosis.
PPARg as a Key Mediator of the
Hepatic Steatotic Function of MLL4
Because the MLL3/4 complexes are
transcriptional coactivators that recog-
nize their target genes via DNA-bound
transcription factors, we hypothesized
that known and/or unknown steatotic
transcription factors expressed in the
liver recruit MLL3/4 complexes to their
steatotic target genes. To test this idea,
we first considered several well defined
hepatic steatotic transcription factors,
including ChREBP, SREBP1c, the liver
X receptors (LXRs, consisting of LXRa
and LXRb), and PPARg. Although the
LXRs and PPARg have been reported
previously to associate with MLL3/4
complexes (Lee et al., 2008a, 2008b),we failed to detect any interaction of MLL3/4 complexes with
ChREBP and SREBP1c (Figure S2A). Although the expression
of many of our steatotic genes was not induced under the
‘‘high-fat and carbohydrate diet’’ condition (60% fat, 20%
carbohydrate) as opposed to our HFD condition (42% fat,
0.2% cholesterol), it was drastically impaired in Lxra/b double
knockout livers (Figures S2B–S2D). These results prompt
us to further investigate whether LXRs are involved with
recruiting MLL3/4 complexes to their target steatotic genes un-
der our HFD paradigm. However, several lines of evidence
strongly suggested that PPARg acts as a major transcrip-
tion factor that recruits MLL3/4 complexes to many of their
hepatic steatotic target genes. First, we examined the recently
reported chromatin immunoprecipitation sequencing (ChIP-
seq) peaks for MLL4 and PPARg during adipogenesis (Leets 17, 1671–1682, November 1, 2016 1673
Figure 2. Steatotic Target Genes of MLL3/4
(A) Heatmap for clustering of steatotic target genes of MLL3/4 into three input pathways for fatty liver formation (Kim et al., 2015).
(B) Heatmap for clustering of HFD-induced steatotic target genes of MLL4 into three input pathways for fatty liver formation.
(C) Schematic of the notion that a significant portion of HFD-induced genes contain ChIP-seq peaks for both MLL4 and PPARg.
See also Figures S1–S3.et al., 2013) because genome-wide ChIP-seq studies for MLL4
and PPARg in fatty livers have not yet been reported, and adi-
pogenesis and hepatic steatosis share a similar gene regulatory
program (Memon et al., 2000; Okumura, 2011). Strikingly, all of
our 15 steatotic genes had ChIP-seq peaks for MLL4 (indicated
by * in Figure 2B and Figure S3), and 11 of these genes (over
73%) showed identical ChIP-seq peaks for both MLL4 and
PPARg (indicated by # in Figure 2B and Figure S3). In addition,
among our 100 high fat diet-induced genes, 75 genes (75%)
displayed ChIP-seq peaks for MLL4, whereas 33 genes (33%)
had identical ChIP-seq peaks for both MLL4 and PPARg (Fig-
ure 2C; Table S1). Second, PPARg has been reported to
directly activate the expression of at least three of our identified
steatotic genes: Cd36 (Tontonoz et al., 1998), Plin2 (Fan et al.,
2009; Kang et al., 2015), and Cidec (Kim et al., 2008; Matsusue
et al., 2008). Third, in the mouse liver carcinoma cell line
Hepa1c1c7, which has been widely utilized as a surrogate
cell line to study liver biology (Bernhard et al., 1973), the
expression of three of our identified steatotic genes, Scd1,
Cd36, and Cidec, was induced by the PPARg ligand rosiglita-
zone, and these inductions were impaired by co-transfected
small hairpin RNA (shRNA) construct against MLL4 (Figure 3A).
Fourth, similar inductions were also observed with livers
from WT mice when 30 mg/kg of rosiglitazone was given
by daily intraperitoneal injection for 7 days, whereas these
hepatic inductions were significantly dampened in Mll4+/
mice (Figure 3B).
Taken together, these results strongly suggest that PPARg is a
major transcription factor that recruits MLL3/4 complexes to a
large fraction of the HFD-inducible target genes of MLL4 (Table
S1), including those involved in promoting fatty liver formation
(Figure 2B).1674 Cell Reports 17, 1671–1682, November 1, 2016Transactivation of Steatotic Target Genes of the MLL4
Complex via PPARg in the Liver
To investigate whether PPARg is indeed responsible for recruit-
ing MLL3/4 complexes to their steatotic target genes, we first
focused on Cd36 in Hepa1c1c7 cells. Among multiple regions
of Cd36 containing identical ChIP-seq peaks for both MLL4
and PPARg as well as the PPAR response element (PPRE) dur-
ing adipogenesis (Lee et al., 2013), we found that a region
approximately 25 kb upstream of the transcription start site
(indicated by a red arrow in Figure 3A and Figure S4) recruits
both PPARg and MLL4 in a PPARg ligand (rosiglitazone)-
enhanced manner in Hepa1c1c7 cells (Figure 4A), coincident
with an increase in H3K4me1 levels (Figure 4B). Moreover,
H3K4me1 levels were significantly dampened by shRNA
against MLL4 (Figure 4B), demonstrating that decoration of
this Cd36-PPRE region by H3K4me1 is carried out by MLL4.
In addition, occupancy of the same region of Cd36 by MLL4
was significantly enhanced by 8 weeks of HFD feeding in WT
livers (Figure 4C). The HFD-enhanced recruitment of MLL4 to
the Cd36-PPRE region was coincident with an increase in
H3K4me1 levels, whereas this increase was significantly abol-
ished in Mll4+/ livers (Figure 4D). Further, recruitment of
MLL4 to the Cd36-PPRE region was significantly induced in
the livers of WT mice when 30 mg/kg of rosiglitazone was given
by daily intraperitoneal injection for 7 days (Figure 4E). Similar
results were also obtained for PPREs in two additional steatotic
target genes of MLL3/4 complexes, Scd1 and Cidec (Figures
4F and 4G; Figures S3H, S3L, and S4). For these experiments,
we used a homemade rabbit antibody against MLL4 whose
specificity toward MLL4 was validated by immunoblotting,
immunoprecipitation, and immunostaining of liver tissues (Fig-
ures S2A, S5A, and S5B).
Figure 3. Critical Roles of MLL4 in the He-
patic Expression of Steatotic Genes
(A) In Hepa1c1c7 hepatocarcinoma cells, rosigli-
tazone, a PPARg ligand, enhances the expression
of three steatotic target genes of MLL4 (Cd36,
Scd1, and Cidec) directed by both PPARg1 and
PPARg2. Knockdown of MLL4 levels using sh-
MLL4 impairs the induction of these genes by
PPARg2 but not by PPARg1. Knockdown of MLL4
was also examined as shown.
(B) Intraperitoneal injection of rosiglitazone results
in induction of the expression of Cd36, Scd1, and
Cidec in WT mice but not inMll4+/mice (n = 4 for
each data point).
All errors are SD.Taken together, these results suggest that PPARg plays crit-
ical roles in recruiting MLL3/4 complexes to their hepatic stea-
totic target genes and that MLL3/4, in turn, direct H3K4me1
decoration of their target enhancer regions.
Pparg2 as a Hepatosteatotic Target Gene of the MLL4
Complex
Because PPARg2 (Figure 5A) is a nutritionally regulated isoform
of PPARg (Medina-Gomez et al., 2007; Vidal-Puig et al., 1996),
and the MLL4 complex was found to play critical roles in HFD-
dependent transcriptome changes in themouse liver (Figure 1C),
we hypothesized that the expression of PPARg2 is either directly
or indirectly regulated by the MLL4 complex. In support of this
idea, the expression of PPARg2, but not PPARg1, was induced
by HFD in WT livers but much less robustly inMll4+/ livers (Fig-
ure 5B). Interestingly, two prominent overlapping ChIP-seq
peaks for both PPARg andMLL4were found around the PPARg2
promoter region (Figure 5C, peaks A and B). Each peak contains
a highly conserved PPRE around its summit region (Figure S4),
raising the interesting possibility that PPARg may autoregulate
transactivation of the PPARg2 promoter by employing the
MLL4 complex as a coactivator. Consistent with this idea, HFD
feeding triggered MLL4 recruitment to both peaks (Figure 5D).
The HFD-dependent recruitment of MLL4 to Pparg-PPRE-A
concurred with its H3K4me1 decoration in WT livers, whereas
HFD feeding failed to robustly induce H3K4me1 decoration in
this region inMll4+/ livers (Figure 5E). In addition, the expressionCell Reporof PPARg2 (but not PPARg1) was readily
induced inWT livers when 30mg/kg of ro-
siglitazone was given by daily intraperito-
neal injection for 7 days (Figure 5F), which
was coincidental with recruitment of
MLL4 to Pparg-PPRE-A (Figure 5G).
These results, together with our find-
ings that PPARg2 is an abundant isoform
under HFD conditions (Figure 5B) and
that MLL4 is required for transactivation
by PPARg2 but not PPARg1 (Figure 3A),
suggest that, in response to lipid excess,
PPARg2 (rather than PPARg1) regulates
the expression of PPARg2 by recruiting
MLL4 to the Pparg2 promoter region,identifying Pparg2 as a steatotic target gene of the MLL4 com-
plex in the liver.
ABL1 Kinase Enhances the Ability of PPARg2 to Interact
with MLL4 in Hepa1c1c7 Cells
Given the central roles of PPARg2 in adipogenesis and HFD-
induced fatty liver formation, we further hypothesized that the
MLL4 complex may selectively interact with PPARg2 and act
as a PPARg2-selective coactivator. In support of this idea, rosi-
glitazone-dependent transactivation of the expression of Scd1,
Cd36, and Cidec by PPARg2 in Hepa1c1c7 cells was impaired
by sh-MLL4, whereas their transactivation by PPARg1 was not
affected by sh-MLL4 (Figure 3A). To further test our hypothesis,
we transfected Hepa1c1c7 cells with FLAG epitope-tagged
PPARg2 and PPARg1, followed by immunoprecipitation with
either control immunoglobulin G (IgG) or anti-MLL4 antibody.
Interestingly, we found that association of PPARg1/2 and
MLL4 requires rosiglitazone that and MLL4 co-immunopurified
PPARg2 more robustly than PPARg1 (27% of input versus 5%
of input; Figure 6A). Moreover, in Hepa1c1c7 cells, although
MLL4-PPARg2 interactions were only slightly increased in the
presence of BCR-ABL fusion protein, a constitutively active
form of ABL1 (24% of input versus 32% of input; Figure 6B),
they were dampened by imatinib, an inhibitor of ABL1 kinase,
in both the absence and presence of BCR-ABL (24% of input
to 12% of input without BCR-ABL and 32% of input to 9% of
input with BCR-ABL; Figure 6B). These results suggest thatts 17, 1671–1682, November 1, 2016 1675
Figure 4. Critical Roles of PPARg in Activa-
tion of the Steatotic Target Genes of MLL4
(A) ChIP for rosiglitazone-enhanced recruitment of
PPARg2 and MLL4 to Cd36-PPRE in Hepa1c1c7
cells transfected with FLAG-tagged PPARg2.
(B) ChIP for rosiglitazone/PPARg2-enhanced
H3K4me1 levels in Cd36-PPRE in Hepa1c1c7
cells transfected with scrambled control shRNA or
sh-MLL4.
(C) ChIP for HFD-enhanced recruitment of MLL4
to Cd36-PPRE in WT livers (n = 4 for each data
point).
(D) ChIP for HFD-enhanced H3K4me1 levels in
Cd36-PPRE in WT livers but not in Mll4+/ livers
(n = 4 for each data point).
(E–G) ChIP for rosiglitazone-enhanced recruitment
of MLL4 to Cd36-PPRE (E), Scd1-PPRE (F), and
Cidec-PPRE (G) in WT livers (n = 4 for each data
point).
The genomic region Untr6 was used as a negative
control throughout all ChIP experiments per-
formed. All errors are SD. See also Figure S4.PPARg2-MLL4 interactions may be enhanced by ABL1-depen-
dent phosphorylation of PPARg2, as described recently for
another coactivator of PPARg2, PGC1a (Keshet et al., 2014).
Consistent with this idea, relative to WT PPARg2, MLL4 inter-
acted slightly more efficiently with a mutant form of PPARg2 in
which the two tyrosine phosphorylation sites by ABL1 were re-
placed by phosphorylation mimicking glutamic acid (20% of
input to 28% of input; Figure 6C). In contrast, MLL4 interacted
less efficiently with a PPARg2 mutant in which the two tyrosine
phosphorylation sites were replaced by non-phosphorylatable
phenylalanine (20% of input to 9% of input; Figure 6C). These re-
sults strongly suggest that ABL1-dependent phosphorylation of
PPARg2 enhances the association of PPARg2 with the MLL4
complex in Hepa1c1c7 liver carcinoma cells.
HFD Enhances the Transactivation Potential of
PPARg2-MLL4 in the Liver via ABL1
During adipogenesis, ABL1 kinase has been reported to
enhance both the protein stability of PPARg2 and the ability of
PPARg2 to interact with its coactivator PGC1a (Keshet et al.,
2014). To further test whether ABL1 similarly enhances the trans-
activation potential of PPARg2-MLL4 in the liver, we first moni-1676 Cell Reports 17, 1671–1682, November 1, 2016tored whether HFD feeding results in
activation of ABL1 in mouse livers. Inter-
estingly, inWT livers, the levels of ABL1 it-
self and PPARg2 were increased with
HFD feeding, whereas the levels of the
a-actin loading control did not change
(Figure 6D). To test whether the increase
in PPARg2 levels is due to an increase
in ABL1 levels, we performed daily intra-
peritoneal injection of 50 mg/kg of the
ABL1 inhibitor imatinib into HFD-fed
mice for 5 consecutive days (Figure 6D)
or ob/ob mice for 4 consecutive days
(Figure 6E). Under both conditions, weobserved a significant decrease in both ABL1 and PPARg2
levels, whereas the levels of a-actin and/or Rbbp5, a common
subunit of Set1-like complexes, did not change significantly (Fig-
ures 6D and 6E). Given the positive correlation between ABL1
and PPARg2 levels (Figures 6D and 6E), we speculate that
HFD-induced ABL1 in WT livers (Figure 6D) or ABL1 in ob/ob
livers (Figure 6E) is likely an activated form. However, an acti-
vated form of ABL1 (ABL1, phosphorylated at tyrosine 245 or
412, which is readily detected with BCR-ABL) was very difficult
to detect in the liver. We reasoned that, relative to BCR-ABL, a
constitutively activated form of ABL, phosphorylation levels of
endogenous ABL1 at tyrosine 245 or 412 may be much lower
or dynamically regulated in the liver.
To determine whether ABL1 also enhances the association of
PPARg2 with the MLL4 complex, we performed co-immunopre-
cipitation experiments between PPARg2 and MLL4 complex-
specific subunits such as ASC-2 and PTIP using the above
ob/ob livers treated with vehicle alone or imatinib. However,
these experiments were not conclusive because of technical
difficulty. However, we found that imatinib decreases the
association of PPARg2 and Rbbp5 (8% of input to 1% of input,
arrowheads in Figure 6F), under a condition for comparable
Figure 5. Pparg2 as a Hepatic Steatotic Target Gene of PPARg2-MLL4
(A) Schematic of PPARg1 and PPARg2 proteins and their genes as well as the known ABL1 kinase-binding site (PXXP) and two tyrosine residues phosphorylated
by ABL1.
(B) qRT-PCR assessment of the expression levels of PPARg1 and PPARg2 in theWT liver under normal CD and HFD feeding conditions using primers specific to
each isoform and primers that detect both isoforms (n = 4 for each data point).
(C) Schematic of ChIP peaks for MLL4 and PPARg in the Pparg locus. Two MLL4 peaks overlapping with PPARg peaks at identical regions are highlighted as
A and B peaks.
(D) ChIP for HFD-enhanced recruitment of MLL4 to Pparg-PPRE-A and Pparg-PPRE-B in WT livers (n = 4).
(E) ChIP for HFD-enhanced H3K4me1 levels in Pparg-PPRE-A in WT livers, which is almost abolished in Mll4+/ livers (n = 4 for each data point).
(F) The expression levels of PPARg1 and PPARg2 in WT livers injected with vehicle or rosiglitazone (n = 4 for each data point).
(G) ChIP for rosiglitazone-enhanced recruitment of MLL4 to Pparg-PPRE-A in WT livers (n = 4 for each data point). The genomic region Untr6 was used as a
negative control.
Errors are SD in (B) and (D)—(G).immunoprecipitation efficiency of PPARg2 (48% of input versus
43% of input, arrows in Figure 6F). These results strongly sug-
gest that ABL1 kinase is likely needed for the association of
PPARg2 with the MLL4 complex in lipid excess ob/ob livers.
Although it remains to be determined how imatinib leads to a
decrease in ABL1 levels, our results raise the interesting possibil-
ity that HFD feeding activates ABL1 kinase in the liver and en-
hances the transactivation potential of PPARg2-MLL4, likely
via phosphorylation of PPARg2, which may contribute to both
stabilization of PPARg2 and its enhanced association with the
MLL4 complex, similar to the findings observed during adipo-
genesis (Keshet et al., 2014). Given that Pparg2 itself is a target
gene of PPARg2-MLL4 (Figure 5), it is also possible that the im-atinib-directed decrease in PPARg2 levels (Figures 6D and 6E)
may result only from suppression of the transactivation potential
of PPARg2-MLL4 because of loss of the interactions between
PPARg2 and the MLL4 complex and not from affecting the pro-
tein stability of PPARg2.
Imatinib Improves the Fatty Liver Condition of ob/ob and
HFD-Fed Mice at Least in Part by Antagonizing
Recruitment of MLL4 to PPREs in Steatotic Target
Genes of MLL4
Based on the potentially critical roles of ABL1 kinase for transac-
tivation potential of PPARg2-MLL4 (Figure 6), we hypothesized
that imatinib will be a powerful inhibitor of the steatotic actionCell Reports 17, 1671–1682, November 1, 2016 1677
Figure 6. Roles of ABL1 Kinase in PPARg2 Levels and Association of PPARg2 and the MLL4 Complex
(A) In Hepa1c1c7 cells transfected with FLAG-tagged PPARg1 and PPARg2, MLL4 shows rosiglitazone-dependent interactions with both PPARg1 and PPARg2,
but the interactions with PPARg2 are much stronger than those with PPARg1.
(B) In Hepa1c1c7 cells transfected with FLAG-tagged PPARg2, coexpression of BCR-ABL slightly enhances the interaction between MLL4 and PPARg2,
whereas imatinib blunts these interactions both in the absence and presence of BCR-ABL.
(C) In Hepa1c1c7 cells, MLL4 showed interactions with FLAG-tagged WT PPARg2, which became slightly stronger with PPARg2-2YE but blunted with
PPARg2-2YF.
(D) Livers from WT mice fed either CD or HFD for 8 weeks and then subjected to daily injection of vehicle alone or imatinib for 5 consecutive days were im-
munoblotted with antibodies against ABL1, PPARg2, and a-actin. The band intensity of ABL1 and PPARg2was quantified in comparisonwith that of a-actin using
ImageJ.
(E) Livers from ob/obmice injected with vehicle alone or imatinib for 4 consecutive days were immunoblotted with antibodies against ABL1, PPARg2, Rbbp5, and
a-actin. The band intensity of ABL1 and PPARg2 was quantified in comparison with that of a-actin using ImageJ.
(F) Liver lysates from ob/obmice injected with vehicle alone or imatinib for 4 consecutive days were immunoprecipitated with anti-PPARg2 antibody, followed by
immunoblotting with anti-Rbbp5 and anti-PPARg2 antibodies. Arrowheads, Rbbp5; arrows, PPARg2. The band intensity of Rbbp5 and PPARg2 was quantified
using ImageJ.of PPARg2-MLL4 in the liver. In support of this idea, recruitment
of MLL4 to Pparg-PPRE-A as well as Cd36-PPRE, Cidec-PPRE,
and Scd1-PPRE in ob/ob livers was significantly dampened by
daily intraperitoneal injection of 50 mg/kg of an ABL1 inhibitor,
imatinib, for 4 consecutive days (Figure 7A; Figure S5C). In addi-1678 Cell Reports 17, 1671–1682, November 1, 2016tion, the expression of Scd1 and Pparg2, two steatotic target
genes of PPARg2-MLL4, in ob/ob livers was strikingly decreased
with 4 days of imatinib treatment (Figure 7B). The expression of
other steatotic target genes of PPARg2-MLL4, such as Cd36,
Cidec, and Plin2, also showed a tendency to decrease, whereas
Figure 7. Improvement of the Fatty Liver Condition of ob/ob Mice by Imatinib
(A) ChIP experiments with ob/ob mice injected with vehicle alone or imatinib reveal that association of MLL4 with Pparg-PPRE-A in ob/ob livers is abolished by
imatinib. ChIP experiments against the genomic region untr6 were done as a negative control.
(B) Expression of the steatotic target genes of PPARg2-MLL4 in ob/ob livers injected with either vehicle alone or imatinib for 4 consecutive days (n = 4 for each
treatment).
(C) Body weights were measured for ob/ob mice injected once a day with vehicle alone or imatinib for 4 consecutive days.
(D) Gross morphology of livers of ob/ob mice after daily injection of vehicle alone or imatinib for 4 consecutive days.
(E) MRI measurement of whole-body fat mass and lean mass after daily injection of vehicle alone or imatinib for 4 consecutive days. Body weights were also
measured.
(F) MRI measurement of liver fat mass and lean mass after daily injection of vehicle alone or imatinib for 4 consecutive days. Liver weights were also measured.
(G) Working model for roles of the ABL1-PPARg2-MLL4 axis in HFD-induced steatosis. HFD activates ABL1 kinase activity, which, in turn, increases the protein
levels of PPARg2 and/or the interactions of PPARg2 with the MLL4 complex, resulting in transactivation of steatotic target genes of the PPARg2-MLL4 complex.
This involves decoration of steatotic target genes of PPARg2-MLL4 with H3K4me1/2 using the MLL4 subunit of the MLL4 complex, and it remains to be
determined whether removal of H3K27me3 by UTX is also involved with this transactivation process.
Errors are SD in (A)–(C) (E), and (F). See also Figures S5–S7.imatinib failed to affect the expression levels of MLL3,MLL4, and
PPARg1 (Figure 7B). In addition, when we performed daily injec-
tion of 50 mg/kg of imatinib into HFD-fed mice for 5 consecutive
days, we observed a significant reduction in the expression of
four of the five steatosis target genes of MLL3/4 we examined
(Figure S6A).
Based on these results, we predicted that imatinib will improve
the fatty liver condition of ob/ob and HFD-fed mice. In support of
this idea, by day 4 of imatinib treatment, we observed that ob/obmice showed a significant decrease in body weight (Figure 7C)
as well as a significant improvement in liver color (i.e., more red-
dish/less fatty with imatinib; Figure 7D). Interestingly, although
imatinib treatment reduced the total body weight by 7%, it
decreased the liver weight by 27% (Figures 7E and 7F), sug-
gesting that imatinib may affect the liver more selectively than
other organs. In support of this idea, our MRI measurement of
fat and lean mass revealed that imatinib treatment results in a
9% decrease in whole-body fat mass and that it reduces liverCell Reports 17, 1671–1682, November 1, 2016 1679
fat mass by 57% (Figures 7E and 7F). Notably, the 9% reduction
in whole-body fat mass in ob/obmice is not visually evident (Fig-
ure S7), suggesting that imatinib-directed improvement in fatty
liver is not due to lack of overall body fats. Similarly, by days 4
and 5 of imatinib treatment, HFD-fed mice showed a significant
decrease in body weight (loss of 7% and 9% of body weight
relative to vehicle-treated controls, respectively; Figure S6B).
However, imatinib did not affect food intake (Figure S6C) but re-
sulted in a dramatic change in liver color (i.e., more reddish/less
fatty with imatinib; Figure S6D) as well as a significant decrease
in liver weight (Figure S6E).
Taken together, our results suggest that ABL1 inhibition leads
to a significant decrease in fat mass in the liver, likely through
interfering with the hepatic steatotic regulatory axis consisting
of ABL1-PPARg2-MLL4, although it also results in a less promi-
nent but still significant decrease in the whole-body fat mass,
supporting a report implicating ABL1 in adipogenesis (Keshet
et al., 2014). Our results also suggest that the hepatic ABL1-
PPARg2-MLL4 axis is perhaps a valuable drug development
target for treating steatosis and NAFLD.
DISCUSSION
Overnutrition, such as an HFD or genetic obesity, triggers
NAFLD, whose pathophysiologic continuum begins with steato-
sis (Hardy et al., 2016). Steatosis results from an imbalance be-
tween FFA/TG acquisition and removal. FFAs/TGs are acquired
from the diet, de novo lipogenesis, and peripheral tissues, and
dietary carbohydrates also activate de novo lipogenesis,
whereas removal of FFAs/TGs involves mitochondrial b-oxida-
tion, assembly of VLDL with apoB for secretion into the blood,
and incorporation into phospholipids and other lipids (Hardy
et al., 2016). In this report, using unbiased RNA-seq analyses,
we made two remarkable discoveries. First, we found that the
hepatic expression of approximately 60% of HFD-controlled
genes requires MLL4 (Figure 1C), establishing MLL4 as a critical
player in overnutrition-induced transcriptome changes in the
mouse liver. Second, we found that MLL3/4 activate the expres-
sion of genes involved with three input pathways for hepatic
FFAs/TGs (i.e., FFA uptake from the periphery, lipogenesis,
and TG synthesis/storage) but not any of the output pathways
(Figures 2A and 2B; Figure S1A), identifying MLL3/4 as major
drivers of hepatic steatosis. Interestingly, it was recently sug-
gested that MLL4 plays more dominant roles than MLL3 in adi-
pogenesis and myogenesis (Lee et al., 2013). Furthermore, the
potent resistance to HFD-induced hepatic steatosis associated
with Mll4+/ and Mll3D/D mice was not observed in our Mll3+/D
mice (Lee et al., 2008a). Taken together, we believe that,
although MLL3 and MLL4 play similar roles in overnutrition-
induced hepatic steatosis, MLL4 is likely a dominant player in
triggering hepatic steatosis.
The striking specificity of MLL3/4 toward three input pathways
for hepatic FFAs/TGs likely reflects the ability of MLL3/4 com-
plexes to physically recognize only a specific subset of transcrip-
tion factors. In support of this idea, among multiple steatotic
transcription factors, we discovered that the MLL4 complex in-
teracts with PPARg (Figure 6A). Our RNS-seq results indeed
suggested that PPARg plays critical roles in recruiting the1680 Cell Reports 17, 1671–1682, November 1, 2016MLL4 complex to many of the HFD-regulated target genes of
MLL4, including genes involved with steatosis (Figures 2B and
2C; Tables S1 and S2). Interestingly, our results further revealed
that PPARg2 but not PPARg1 likely recruits theMLL4 complex to
its steatotic target genes during overnutrition-induced steatosis.
First, PPARg2 showed a 5.4-fold higher affinity than PPARg1 in
interactions with the MLL4 complex (Figure 6A). Second, MLL4
is required for transactivation of its steatotic target genes by
PPARg2 but not by PPARg1 in the Hepa1c1c7 hepatocarcinoma
cell line (Figure 3A). Third, the expression of PPARg2 but not
PPARg1 is highly induced under our HFD condition, resulting in
4-fold higher levels of PPARg2 than of PPARg1 (Figure 5B).
Coupled with the higher affinity of PPARg2 toward the MLL4
complex, this can result in a 21.6-fold (5.4- 3 4-fold) higher
chance for PPARg2 to associate with the MLL4 complex in com-
parison with PPARg1. Fourth, ABL1 kinase is known to enhance
the association of PPARg2 with its coactivator PGC1a via phos-
phorylation of PPARg2 during adipogenesis (Keshet et al., 2014),
and, similarly, we found that imatinib, an ABL1 kinase inhibitor,
decreases the association of PPARg2 with MLL4 in Hepa1c1c7
cells (Figure 6B), suggesting that imatinib impinges on the inter-
actions of PPARg2 with the MLL4 complex. We believe that this
involves blocking the phosphorylation of PPARg2 by ABL1 ki-
nase because PPARg2-MLL4 associations were dampened by
mutation of two tyrosine residues that are phosphorylated by
ABL1 kinase to non-phosphorylatable phenylalanine (Figure 6C).
Of note, transfection of identical amounts of our expression vec-
tors for PPARg1 and PPARg2 into Hepa1c1c7 cells resulted in
approximately 4- to 5-fold higher levels of PPARg2 proteins in
comparison with PPARg1 protein levels. Combined with the
similar affinity of WT PPARg2 and activated PPARg2-2YE
mutant toward MLL4 (Figure 6C), these results raise the inter-
esting possibility that ABL1 in Hepa1c1c7 cells may be a consti-
tutively activated mutant form. Although the two phosphorylated
tyrosine residues in PPARg2 are expected to be either directly or
indirectly involved in interacting with one or more subunits of
MLL3/4 complexes, the identity of the PPARg2-interacting sub-
units and the molecular nature of the interaction interface remain
to be determined. Fifth, we found that HFD activates ABL1 ki-
nase in the liver (Figure 6D), and intraperitoneal injection of ima-
tinib into ob/obmice or HFD-fedmice led to a dramatic reduction
in PPARg2 levels in their livers (Figures 6D and 6E). Moreover,
imatinib drastically reduced recruitment of MLL4 to its steatotic
target genes in ob/obmice (Figure 7A; Figure S5C). These results
strongly support crucial roles of PPARg2 in recruiting the MLL4
complex to its steatotic target genes. Overall, our results identify
an interesting regulatory axis in hepatic steatosis consisting of
overnutrition-induced ABL1 kinase, PPARg2-specific phosphor-
ylation by ABL1 and the resulting increase in the protein stability
of PPARg2 and/or in the binding affinity of PPARg2 towardMLL4
complex, and transactivation of steatotic target genes of the
PPARg2-MLL4 complex (Figure 7G).
Epigenetic regulation of steatosis has been poorly under-
stood. Our identification of the ABL-PPARg2-MLL4 axis begins
to provide critical insights into this issue. Through this axis, over-
nutrition such as an HFD or genetic obesity results in steatosis by
mobilizing the MLL4 complex to the hepatic steatotic target
genes of PPARg2-MLL4, which, in turn, facilitates their open
chromatin formation. In particular, we have shown that recruit-
ment of theMLL4 complex leads to an increase in the open chro-
matinmark H3K4me1 (Figures 4B and 4D and 5E), and it remains
to be determined in the future whether UTX in the MLL4 complex
also plays important roles in hepatic steatosis via its ability to re-
move the repressive chromatin mark H3K27me3 (Figure 7G).
PPARg2 is a nutrition-induced factor in both adipogenesis and
hepatic steatosis. Although themolecular basis for this induction
during adipogenesis has been relatively well characterized
(Rosen, 2005), little is known about how the expression of
PPARg2 is induced in response to overnutrition in the liver. Our
results suggest that Pparg2 itself is a direct target gene of the
ABL1-PPARg2-MLL4 axis. First, the promoter region of Pparg2
contains at least two common ChIP-seq peaks for both MLL4
and PPARg (Figure 5C), which we found to recruit MLL4 in
response to HFD feeding (Figure 5D), concomitant with an
MLL4-dependent increase in H3K4me1 levels (Figure 5E). Rosi-
glitazone treatment also triggered recruitment of MLL4 to these
peaks in the liver, confirming that they represent functional
PPRE for PPARg (Figure 5G). Second, in response to HFD, the
expression of PPARg2 but not PPARg1 was induced in the liver
(Figure 5B). Moreover, inhibition of ABL1 kinase activity in ob/ob
or HFD-fed livers led to a striking reduction in PPARg2 mRNA
levels (Figure 7B; Figure S6A) with a concomitant decrease in
MLL4 recruitment to the Pparg2 promoter region (Figure 7A).
In summary, this study identifies a critical regulatory axis in
overnutrition-directed steatosis, and we also present this
ABL1-PPARg2-MLL4 axis as a potential target for anti-steatosis
drug development. In addition to ABL1 inhibitors, any small
molecule that antagonizes the H3K4MT enzymatic activity of
MLL4 may improve the fatty liver condition of NAFLD patients.
However, other steatotic transcription factors may also play
roles in recruiting MLL3/4 complexes to their steatotic target
genes. In particular, MLL3/4 complexes may be involved with
de novo lipogenesis directed by the LXRs in the liver (Fig-
ure S2B–S2D; Hong and Tontonoz, 2014). Future studies should
be directed at testing this possibility as well as identifying addi-
tional steatotic transcription factors that mediate the hepatic
steatotic function of MLL3/4 complexes. Finally, it should be
noted that imatinib, although it was originally developed as a
specific inhibitor of BCR-ABL, also inhibits other tyrosine kinase
receptors (Buchdunger et al., 2002). These include platelet-
derived growth factor (PDGF) receptor, which mediates the
steatosis action of PDGF-C (Campbell et al., 2005). Therefore,
it remains to be determined whether the powerful anti-steatotic
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